Selexis SA to Give Away â‚¬ 25,000 SUREvariant Screening Service Project at BIO 2011
Celebrating Launch of New Service in Support of Biologic Lead Identification
Geneva, Switzerland (PRWEB) June 24, 2011
Selexis SA is a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs. The Company announced today it will be showcasing the new Selexis SUREvariant ScreeningÃ¢“¢ Service by giving away one free SUREvariant Screening at the 2011 BIO International Convention being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.
Using the Selexis SUREvariant Screening Platform, Selexis will generate high-performance Selexis SUREpoolsÃ¢“¢ for up to 4 monoclonal antibodies or recombinant protein variants, each SUREpool expressing a unique protein of interest. Selexis will then transfer cell culture supernatants (Selexis SUREnatantsÃ¢“¢) from each of the Selexis SUREpools to contest winner for use in preclinical testing.
Contestants may enter the contest by dropping off a business card at the Selexis booth 1906 during exhibit hall hours. There is no purchase necessary to enter the content. Limit one entry per company. The winner will be chosen by random ballot on the last day of the conference, Thursday, June 30, 2011.
As described by industry thought leaders in recent technical conferences, producing preclinical lead proteins in a cGMP production platform can significantly improve preclinical decisions by reducing or eliminating heterogeneity of recombinant protein batches. The heterogeneity is caused by multiple technologies used in protein expression and impact mainly post-translational modifications.
- Rapid development of up to four (4) Selexis SUREpools, each expressing a monoclonal antibody or recombinant protein variant of interest
- Transfer to contest winner Selexis SUREnatant for each Selexis SUREpool
- Program value of over &eur; 25,000
Contest Project Scope Includes:
- Standard DNA cloning into Selexis SUREtech VectorsÃ¢“¢
- Transfection using Selexis SUREfection ProceduresÃ¢“¢
- Stable pool selection using Selexis SURE procedures
- Shipment of Selexis SUREnatants to contest winner
Contest Program Conditions:
- Contest winner will supply genes of interest in format which can be directly cloned into Selexis SUREtech Vectors
- Other terms and conditions apply ““ see a Selexis Business Development representative at the Selexis booth for details
- No purchase necessary to enter
- Limit one entry per company
Selexis will be exhibiting in booth number #1906 located in Hall A ““ Discovery Zone (http://e.mybio.zerista.com/exhibitor/member/17326). For the exhibit hall schedule, visit: http://e.mybio.zerista.com/event/print
About Selexis SUREvariant ScreeningÃ¢“¢
Selexis’ SUREvariant ScreeningÃ¢“¢ accelerates and improves outcomes from displayed library selection campaigns by reducing the time and the number of steps to identify potential lead candidates. The SUREvariant ScreeningÃ¢“¢ platform used at Selexis can generate panels of up to 500 CHO-M cell pools (SUREpoolsÃ¢“¢), each expressing different protein variants. Typical expression levels in the supernatants (SUREnatantsÃ¢“¢) for MAbs vary between 50-500 mg/L. The SUREnatantsÃ¢“¢ containing the recombinant proteins expressed with mammalian post-translational modifications can be readily assessed for activity. Subsequently, Selexis SUREpoolsÃ¢“¢ top candidates can be banked (stored) and then reused for further assays. The top SUREpoolÃ¢“¢ candidate is transferred to the Selexis’ SURE Cell LineÃ¢“¢ Development platform to generate a high producing clonal cell line ready for cGMP manufacturing. The entire process from SUREvariant ScreeningÃ¢“¢ to the clonal cell line can be as short as 14 weeks. Selexis SUREvariant ScreeningÃ¢“¢ can reduce your development costs by over $500,000 per clinical candidate!
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company’s SURE Cell Line DevelopmentÃ¢“¢ Technology Platform is based on Selexis Genetic ElementsÃ¢“¢ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech VectorsÃ¢“¢, Selexis SUREfectionÃ¢“¢ Transfection Methods, Selexis SUREvariant ScreeningÃ¢“¢ and the proprietary Selexis SURE CHO-M Cell LineÃ¢“¢.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebmonoclonal_antibodies/bio_selexis/prweb8599244.htm